

A Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)


Have you been newly diagnosed with NSCLC with KRAS^{G12C} mutation?

Consider participating in a clinical study (849-007 / CA239-0009, also called KRYSTAL-7), for patients diagnosed with NSCLC with KRAS^{G12C} mutation who have received no prior treatments.



BMS-NSCLCTrials.com/K-7

About the Krystal-7 Clinical Trial



The phase 3 portion of the KRYSTAL-7 clinical study is designed to help researchers learn whether the study drug adagrasib, in combination with pembrolizumab, works to treat patients diagnosed with NSCLC with a KRAS^{G12C} mutation and PD-L1 expression level ≥50%, with no prior treatments.

Participation is completely voluntary. Your privacy will be maintained during and after the study. Requesting information about this research study does not obligate you to take part in it.

People who take part in clinical studies are key to advancing medical research. By taking part in the KRYSTAL-7 study, you will be aiding medical research which may help others with NSCLC in the future. Over the course of the study, a participant's health may get better, get worse, or stay the same.

People who are considering taking part in the study will be given a list of risks and possible discomforts before agreeing to participate. As with any medication, there may be a reaction to the study drug.

You may be eligible to join the KRYSTAL-7 trial if you are at least 18 years of age and:

- ✓ Have a specific type of lung cancer known as NSCLC (either squamous or non-squamous NSCLC)
- ✓ Your cancer has a specific genetic mutation called KRAS^{G12C}
- ✓ Your tumors have a high level of a protein called PD-L1, with expression of 50% or higher
- ✓ Your cancer is unresectable (cannot be removed by surgery) and either locally advanced or metastatic (spread to other parts of the body) this would be your first treatment for this stage of cancer
- ✓ The presence of the KRAS^{G12C} mutation and the PD-L1 level has been confirmed using specific tests approved by the study sponsor.

If you're interested in joining the KRYSTAL-7 study, talk to your doctor. Together, you can decide if participating may be right for you. If you are eligible for the study and choose to participate, you may receive the study-related medical care, laboratory work, and procedures at no cost, if applicable at your location.

For Physicians

To discuss a potential patient referral, please contact your nearest Principal Investigator or site staff to learn more.

